CIS Pharma's antibody-drug-conjugate in comparison to conventional ADCs -

Zum Inhalt springen

Suche nach:

HOME
COMPANY
ONCOLOGY
OPHTHALMOLOGY
BIOMATERIALS
PARTNERING
NEWS
CONTACT

CIS Pharma’s antibody-drug-conjugate in comparison to conventional ADCsOHO Design2021-09-28T05:56:16+02:00

CIS Pharma AG

Company
Oncology
Ophthalmology
Biomaterials
Partnering

Innovation since 1952

Career
Login
Disclaimer
Privacy Policy
About Cookies

CIS Pharma AG

Hauptstrasse 159
4416 Bubendorf
Switzerland
+41 61 935 53 23
info@cis-pharma.com

LinkedIn Facebook

This website uses cookies to improve your experience. Accept Privacy Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

immer aktiv

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SPEICHERN & AKZEPTIEREN

Nach oben